Mainz Biomed B.V. (MYNZ) AI Stock Analysis

• Market Cap: $10.60M
• Dividend Yield: N/A
• Average Volume (3M): 350.23K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.40
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 19
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -2.65
• Shares Outstanding: 9,060,142
• 10 Day Avg. Volume: 923,862
• 30 Day Avg. Volume: 350,228
• PEG Ratio: >-0.01
• Price to Book (P/B): 0.69
• Price to Sales (P/S): 4.68
• P/FCF Ratio: -0.24
• Enterprise Value/Market Cap: 0.00
• Enterprise Value/Revenue: 0.00
• Enterprise Value/Gross Profit: 0.00
• Enterprise Value/Ebitda: 0.00
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 49 Neutral
• Price Target: $1.50 ▲(29.31% Upside)

Overall score is held back primarily by weak financial performance (ongoing losses, high leverage, and negative operating cash flow with reliance on financing). Technical indicators are moderately supportive in the near term (above 20D/50D with neutral momentum), but the longer-term trend remains negative. Valuation impact is neutral because P/E and dividend yield are unavailable.

Positive Factors

Clinical accuracy - pancreatic test

Topline feasibility results with extremely high sensitivity and specificity provide durable clinical validation for Mainz Biomed's blood-based pancreatic cancer program. Strong accuracy supports regulatory submissions, payer discussions, and clinician trust, materially improving long-term commercial and R&D prospects.

Regulatory approval and market access

Swissmedic registration and a commercial launch in Switzerland create a durable foothold in a regulated European market. This regulatory milestone lowers commercialization risk, enables revenue generation and reimbursement pathways, and establishes precedent for approvals in other jurisdictions.

Distribution and lab partnerships

Inclusion in DoctorBox's portfolio and reliance on the European Oncology Lab for analysis leverage established distribution and laboratory infrastructure. These durable partnerships reduce go-to-market friction, support scalable test processing, and improve the company's ability to drive sustained commercial adoption.

Negative Factors

Negative operating cash flow

Sustained negative operating cash flow shows the business is not self-funding and relies on external financing. Over months this erodes flexibility, increases refinancing and dilution risk, and can force the company to prioritize liquidity over commercialization and long-term R&D investments.

High leverage and weak equity cushion

A rising debt-to-equity ratio and limited equity reduce solvency resilience if commercialization slows. Structurally weak balance sheet increases borrowing costs, limits strategic optionality, and raises the likelihood management must seek dilutive financing or cut investments during adverse periods.

Revenue stagnation and persistent losses

Failure to outgrow 2020 revenue levels coupled with ongoing large EBIT and net losses indicates difficulty scaling commercial traction. Persistent unprofitability undermines internal cash generation, sustaining reliance on external capital and challenging the path to durable, self-sustaining growth.

Mainz Biomed B.V. Business Overview & Revenue Model

Company Description

Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.

How the Company Makes Money

Mainz Biomed generates revenue primarily through the commercialization of its diagnostic tests, which are sold to healthcare providers, hospitals, and laboratories. The company may also engage in partnerships with pharmaceutical companies and research institutions, providing additional revenue streams through collaborative research and development projects. Furthermore, Mainz Biomed may benefit from licensing agreements for its proprietary technologies, enabling it to earn royalties from other entities that utilize its innovations in their own offerings. Additionally, government grants and funding for cancer research initiatives could contribute to the company's earnings, although specific partnership details and revenue figures are not disclosed.

Mainz Biomed B.V. Financial Statement Overview

Summary

Mainz Biomed B.V. is facing significant financial challenges, including negative profitability and high leverage. The company shows some improvements in equity and free cash flows, but sustained negative margins and reliance on financing pose risks. A strategic focus on revenue growth and cost management is crucial for future stability.

Income Statement

Mainz Biomed B.V. has shown fluctuating revenues with recent stagnation, failing to surpass the 2020 revenue levels. Despite some improvement in gross profit margins, the company continues to incur substantial EBIT and net losses, indicating persistent profitability challenges. Net profit margin remains deeply negative, emphasizing ongoing financial hurdles.

Balance Sheet

The company exhibits high leverage with a rising debt-to-equity ratio, indicating potential financial risk. Stockholders' equity has improved recently, but overall equity is still relatively low compared to total assets, suggesting limited financial stability. Return on Equity remains negative, reflecting unprofitability.

Cash Flow

Operating cash flow has been consistently negative, although free cash flow has shown some improvement. Financing activities have been a major source of cash, highlighting reliance on external funding. The operating cash flow to net income ratio is concerning, as cash flows are not covering net losses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	659.93K	893.99K	895.48K	529.88K	577.35K	493.56K
Gross Profit	-54.50K	574.88K	509.66K	182.15K	177.62K	123.08K
EBITDA	-17.83M	-19.56M	-25.01M	-25.72M	-11.28M	-257.64K
Net Income	-18.97M	-21.65M	-26.30M	-26.45M	-11.69M	-586.89K
Balance Sheet
Total Assets	9.80M	13.24M	15.41M	20.24M	10.04M	673.27K
Cash, Cash Equivalents and Short-Term Investments	1.91M	6.24M	7.07M	17.14M	8.73M	122.57K
Total Debt	3.09M	3.27M	7.42M	3.23M	2.58M	2.98M
Total Liabilities	7.28M	7.19M	12.16M	6.14M	3.68M	3.41M
Stockholders Equity	2.52M	6.05M	3.25M	14.10M	6.36M	-2.74M
Cash Flow
Free Cash Flow	-15.60M	-17.34M	-23.84M	-15.43M	-3.24M	-478.42K
Operating Cash Flow	-15.46M	-17.09M	-21.94M	-14.77M	-3.22M	-468.74K
Investing Cash Flow	-229.28K	-198.82K	-1.90M	-658.48K	1.20M	-9.69K
Financing Cash Flow	16.72M	16.60M	14.23M	23.94M	10.61M	396.68K

Mainz Biomed B.V. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.16
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MYNZ, the sentiment is Negative. The current price of 1.16 is below the 20-day moving average (MA) of 1.17, below the 50-day MA of 1.19, and below the 200-day MA of 1.81, indicating a bearish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 45.38 is Neutral, neither overbought nor oversold. The STOCH value of 18.25 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MYNZ.

Mainz Biomed B.V. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
INBS	59 Neutral	$14.64M	-0.98	-223.45%	―	3.26%	65.96%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MYNZ	49 Neutral	$10.60M	―	―	―	―	―
NDRA	42 Neutral	$5.26M	-0.35	-236.34%	―	―	98.86%
ISPC	42 Neutral	$3.11M	-0.04	-296.20%	―	-67.73%	58.35%

Mainz Biomed B.V. Corporate Events

Mainz Biomed B.V. Amends Articles to Boost Share Capital

On November 13, 2025, Mainz Biomed B.V. amended its Articles of Association to decrease the nominal value of its shares, increase its authorized share capital, and eliminate the issuance of fractional shares. These changes are expected to enhance the company’s financial flexibility and potentially improve its market positioning by allowing for a greater number of shares to be issued, which could attract more investors and stakeholders.

The most recent analyst rating on (MYNZ) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Mainz Biomed B.V. stock, see the MYNZ Stock Forecast page.